Recently, the degree of signal transducer and activator of transcription 3 (STAT3) activity has emerged as an important biomarker in targeted therapy of cancer patients, including glioblastoma patients [3,4], suggesting that STAT3 inhibitors may be an essential strategy for the treatment of glioblastoma. This evidence concerns the gene STAT3 and glioblastoma.